Insights

Market Expansion Oxipit's recent acquisition by Sectra and the launch of new CE-certified AI tools like ChestLink, CT Eye, and MSK Eye indicate a strategic move to expand into diverse radiology workflows and geographies, presenting opportunities to engage healthcare institutions seeking comprehensive imaging solutions.

Regulatory Credentials With multiple CE certifications and CE Class 2B approval for autonomous AI solutions, Oxipit demonstrates strong compliance and reliability, making their products especially appealing to hospitals and clinics looking to adopt trusted, certified AI tools for diagnostic support.

Global Adoption Trusted by healthcare institutions worldwide and partnered with leading firms like Blackford Analysis and Unilabs, Oxipit’s solutions are positioned for widespread adoption, offering sales potential through organizations that are adopting or expanding AI-driven radiology services.

Growth Potential While currently generating up to $1M in revenue with significant funding of $4.2M, Oxipit’s ongoing product development, including autonomous AI capabilities and new workflows, suggests opportunities to upsell and expand within existing client bases as their market presence grows.

Technology Leadership Oxipit’s innovative technology stack and autonomous AI solutions, such as ChestLink, place it at the forefront of radiology AI development, making it a compelling partner for health systems aiming to modernize diagnostic workflows with cutting-edge, scalable AI tools.

Similar companies to Oxipit

Oxipit Tech Stack

Oxipit uses 8 technology products and services including SaltStack, WordPress, Cookie Notice, and more. Explore Oxipit's tech stack below.

  • SaltStack
    Build Automation
  • WordPress
    Content Management System
  • Cookie Notice
    Cookie Compliance
  • Shopify
    E-commerce
  • Google Workspace
    Email
  • Swiper
    Javascript Libraries
  • Python
    Programming Languages
  • reCAPTCHA
    Security

Oxipit's Email Address Formats

Oxipit uses at least 1 format(s):
Oxipit Email FormatsExamplePercentage
First@oxipit.aiJohn@oxipit.ai
69%
Last@oxipit.aiDoe@oxipit.ai
25%
First.Last@oxipit.aiJohn.Doe@oxipit.ai
6%

Frequently Asked Questions

Where is Oxipit's headquarters located?

Minus sign iconPlus sign icon
Oxipit's main headquarters is located at Vilnius, Vilniaus Miestas Lithuania. The company has employees across 1 continents, including Europe.

What is Oxipit's official website and social media links?

Minus sign iconPlus sign icon
Oxipit's official website is oxipit.ai and has social profiles on LinkedInCrunchbase.

What is Oxipit's NAICS code?

Minus sign iconPlus sign icon
Oxipit's NAICS code is 5112 - Software Publishers.

How many employees does Oxipit have currently?

Minus sign iconPlus sign icon
As of April 2026, Oxipit has approximately 23 employees across 1 continents, including Europe. Key team members include Chief Executive Officer: P. C.Chief Ai Officer, Co-Founder: G. P.Chief Commercial Officer (cco): D. C.. Explore Oxipit's employee directory with LeadIQ.

What industry does Oxipit belong to?

Minus sign iconPlus sign icon
Oxipit operates in the Software Development industry.

What technology does Oxipit use?

Minus sign iconPlus sign icon
Oxipit's tech stack includes SaltStackWordPressCookie NoticeShopifyGoogle WorkspaceSwiperPythonreCAPTCHA.

What is Oxipit's email format?

Minus sign iconPlus sign icon
Oxipit's email format typically follows the pattern of First@oxipit.ai. Find more Oxipit email formats with LeadIQ.

How much funding has Oxipit raised to date?

Minus sign iconPlus sign icon
As of April 2026, Oxipit has raised $4.2M in funding. The last funding round occurred on Jan 19, 2023 for $4.2M.

When was Oxipit founded?

Minus sign iconPlus sign icon
Oxipit was founded in 2017.

Oxipit

Software DevelopmentVilniaus Miestas, Lithuania11-50 Employees

Since 2017, Oxipit has been building radiology AI you can trust—tools that analyze chest X-rays, support faster diagnoses, and ease the workload for clinical teams. As imaging volumes rise and pressure on radiology departments grows, our mission is clear: reduce the burden, support precision, and help radiologists focus on what matters most.

Oxipit's CXR Suite is a certified, powerful portfolio of radiology AI tools designed to streamline chest X-ray diagnostics from start to finish. Trusted by healthcare institutions globally, the CXR Suite brings together three advanced solutions:


• ChestLink – the world’s first autonomous AI for normal chest X-rays, safely removing up to 40% of studies from radiologists’ workloads with 99.9% sensitivity.

• ChestEye – an on-screen assistant that detects 75 findings, supporting diagnostic quality and day-to-day decision-making.

• ChestQuality – a second set of eyes—continuously reviewing reports to support accuracy and catch overlooked findings.


No matter where you are in your AI journey, the Oxipit CXR Suite meets you there. Start with the tools that fit your needs today—and scale as your workflow evolves.

The future of radiology AI is flexible—and autonomous.

Section iconCompany Overview

Headquarters
Vilnius, Vilniaus Miestas Lithuania
Website
oxipit.ai
NAICS Code
5112 - Software Publishers
Founded
2017
Employees
11-50

Section iconFunding & Financials

  • $4.2M

    Oxipit has raised a total of $4.2M of funding over 3 rounds. Their latest funding round was raised on Jan 19, 2023 in the amount of $4.2M.

  • $1M

    Oxipit's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $4.2M

    Oxipit has raised a total of $4.2M of funding over 3 rounds. Their latest funding round was raised on Jan 19, 2023 in the amount of $4.2M.

  • $1M

    Oxipit's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.